[1]杨月琴,叶中绿.儿童急性淋巴细胞白血病早期治疗反应对预后价值的研究[J].医学信息,2020,33(04):51-54.[doi:10.3969/j.issn.1006-1959.2020.04.016]
 YANG Yue-qin,YE Zhong-lv.Study on Early Prognostic Value of Childhood Acute Lymphoblastic Leukemia in Response to Treatment[J].Medical Information,2020,33(04):51-54.[doi:10.3969/j.issn.1006-1959.2020.04.016]
点击复制

儿童急性淋巴细胞白血病早期治疗反应对预后价值的研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年04期
页码:
51-54
栏目:
综述
出版日期:
2020-02-15

文章信息/Info

Title:
Study on Early Prognostic Value of Childhood Acute Lymphoblastic Leukemia in Response to Treatment
文章编号:
1006-1959(2020)04-0051-04
作者:
杨月琴叶中绿
(1.广东医科大学研究生学院,广东 湛江 524001;2.广东医科大学附属医院儿童医学中心,广东 湛江 524001)
Author(s):
YANG Yue-qinYE Zhong-lv
(1.Graduate School of Guangdong Medical University,Zhanjiang 524001,Guangdong,China;2.Children’s Medical Center,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524001,Guangdong,China)
关键词:
急性淋巴细胞白血病诱导化疗治疗反应预后价值
Keywords:
Acute lymphoblastic leukemiaInduction chemotherapyTreatment responsePrognostic value
分类号:
R733.71
DOI:
10.3969/j.issn.1006-1959.2020.04.016
文献标志码:
A
摘要:
儿童急性淋巴细胞白血病(ALL)是一组高度异质性的恶性血液病,具有发病急、病死率高的特点。采用以分层治疗为指导、化疗药物不断优化组合的治疗策略,使儿童ALL患者的预后得到很大改善。早期治疗反应是分层治疗的重要指标, D8泼尼松敏感试验、D15骨髓缓解状态、D33骨髓缓解状态和D33微小残留病的早期治疗反应是ALL患儿一个独立预后因素,且ALL患儿诱导化疗后的外周血细胞计数也作为早期治疗反应指标受到临床广泛关注。本文从以上早期治疗反应对儿童ALL患者预后的影响作一综述。
Abstract:
Acute lymphoblastic leukemia (ALL) in children is a group of highly heterogeneous malignant hematological diseases with characteristics of acute onset and high mortality. Adopting stratified therapy as the guide and continuously optimizing the combination of chemotherapeutic drugs, the prognosis of children with ALL has been greatly improved. Early treatment response is an important indicator of stratified treatment. D8 prednisone sensitivity test, D15 bone marrow remission status, D33 bone marrow remission status, and early treatment response of D33 minimal residual disease are independent prognostic factors in children with ALL and peripheral blood cell counts after induction chemotherapy in children with ALL have also received widespread clinical attention as indicators of early treatment response. This article summarizes the impact of the above early treatment responses on the prognosis of children with ALL.

参考文献/References:

[1]Kato M,Manabe A.Treatment and biology of pediatric acute lymphoblastic leukemia[J].Pediatrics International,2018,60(1):4-12. [2]Pieters R,de Groot-Kruseman H,van der Velden V,et al.Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring:Study ALL10 From the Dutch Childhood Oncology Group[J].Journal of Clinical Oncology,2016,34(22):2591-2601. [3]Stary J,Zimmermann M,Campbell M,et al.Intensive Chemotherapy for Childhood Acute Lymphoblastic Leukemia:Results of the Randomized Intercontinental Trial ALL IC-BFM 2002[J].Journal of Clinical Oncology,2014,32(3):174-184. [4]中国抗癌协会淋巴瘤专业委员会,中国淋巴瘤南方协作组,中国临床肿瘤学会抗淋巴瘤联盟.长春碱类药物治疗恶性淋巴瘤中国专家共识[J].中国肿瘤临床,2017,44(5):193-198. [5]崔蕾,张瑞东,高超,等.儿童急性淋巴细胞白血病早期治疗反应评估与预后价值[J].中国实验血液学杂志,2014,22(2):298-303. [6]高敬.泼尼松诱导试验与儿童急性淋巴细胞白血病预后关系的Meta分析[D].西南医科大学,2018. [7]Moricke A,Zimmermann M,Reiter A,et al.Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000[J].Leukemia,2010,24(2):265-284. [8]任媛媛,邹尧,常丽贤,等.泼尼松反应在CCLG-ALL 2008方案中预后价值的探讨[J].中国实验血液学杂志,2015,23(3):642-646. [9]郑瑜,蔡云望,符启昌,等.急性淋巴细胞白血病患儿早期治疗反应与预后关系[J].中国实验血液学杂志,2018,26(3):733-737. [10]Lauten M,Moricke A,Beier R,et al.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial:differential effects in precursor B-cell and T-cell leukemia[J].Haematologica,2012,97(7):1048-1056. [11]Koka A,Saygin C,Uzunaslan D,et al.A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia:Prognostic predictors and interruptions during protocol[J].Leukemia Research,2014,38(6):699-705. [12]Salzer WL,Devidas M,Carroll WL,et al.Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001:a report from the children’s oncology group[J].Leukemia,2010,24(2):355-370. [13]Laughton SJ,Ashton LJ,Kwan E,et al.Early Responses to Chemotherapy of Normal and Malignant Hematologic Cells Are Prognostic in Children With Acute Lymphoblastic Leukemia[J].Journal of Clinical Oncology,2005,23(10):2264-2271. [14]Conter V,Bartram CR,Valsecchi MG,et al.Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia:results in 3184 patients of the AIEOP-BFM ALL 2000 study[J].Blood,2010,115(16):3206-3214. [15]Farkas T,Müller J,Erdelyi DJ,et al.Absolute Lymphocyte Count(ALC)after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia[J].Pathology&Oncology Research,2017,23(4):889-897. [16]徐瑞琴,陆小云,张敏.急性白血病缓解期微小残留病灶与预后的关系[J].临床血液学杂志,2016,29(2):209-212. [17]Schrappe M,Valsecchi MG,Bartram CR,et al.Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL:results of the AIEOP-BFM-ALL 2000 study[J].Blood,2011,118(8):2077-2084. [18]Borowitz MJ,Devidas M,Hunger SP,et al.Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors:a Children’s Oncology Group study[J].Blood,2008,111(12):5477-5485. [19]Feng J,Feng J Wang Z,et al.Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma:a meta-analysis[J].International Journal of Hematology,2012,95(2):143-148. [20]Rabin KR,Gramatges MM,Borowitz MJ,et al.Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia[J].Pediatric Blood&Cancer,2012,59(3):468-474. [21]Hirase S,Hasegawa D,Takahashi H,et al.Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia[J].International Journal of Hematology,2015,102(5):594-601. [22]Gupta A,Kapoor G,Jain S,et al.Absolute Lymphocyte Count Recovery Independently Predicts Outcome in Childhood Acute Lymphoblastic Leukemia:Experience From a Tertiary Care Cancer Center of a Developing Country[J].J Pediatr Hematol Oncol,2015,37(3):e143-e149. [23]黎巧茹,柯志勇,谭惠珍,等.儿童急性淋巴细胞白血病诱导治疗结束时外周血淋巴细胞数与预后的关系[J].热带医学杂志,2016,16(10):1267-1271. [24]Rolf N,Rolf N,Smolen KK,et al.Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia[J].Cancer Immunology,2018,67(2):225-236. [25]Cheng Y,Luo Z,Yang S,et al.The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood B-lineage acute lymphoblastic leukemia[J].Leukemia Research,2014,39(2):144-150. [26]Zeidler L,Zimmermann M,Moricke A,et al.Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome[J].Haematologica,2012,97(3):402-409. [27]De Angulo G,Yuen C,Palla SL,et al.Absolute lymphocyte count is a novel prognostic indicator in ALL and AML[J].Cancer,2008,112(2):407-415. [28]Long Y,Wang T,Gao Q,et al.Prognostic significance of pretreatment elevated platelet count in patients with colorectal cancer:a meta-analysis[J].Oncotarget,2016,7(49):81849. [29]Lee CH,Lin YJ,Lin CC,et al.Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma[J].Liver International,2015,35(10):2327-2336. [30]Kopp HG,Placke T,Salih HR.Platelet-Derived Transforming Growth Factor-Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity[J].Cancer Research,2009,69(19):7775-7783. [31]黄喆,刘文君,曹汴川,等.儿童急性淋巴细胞白血病血小板参数及血小板膜糖蛋白临床意义研究[J].中国实用儿科杂志,2017,32(5):366-370. [32]Sharma D,Brummel-Ziedins KE,Bouchard BA,et al.Platelets in Tumor Progression:A Host Factor That Offers Multiple Potential Targets in the Treatment of Cancer[J].Journal of Cellular Physiology,2014,229(8):1005-1015. [33]张傲利,陈晓娟,邹尧,等.不同血小板水平儿童急性淋巴细胞白血病的临床特征及预后研究[J].中国当代儿科杂志,2019,21(8):766-771. [34]Faderl S,Thall PF,Kantarjian HM,et al.Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission[J].British Journal of Haematology,2002,117(4):869-874. [35]Grunnan JD,Rosth?j S.Time course of peripheral blood count recovery during induction chemotherapy for childhood acute lymphoblastic leukemia[J].Hematology,2019,24(1):467-472.

相似文献/References:

[1]黄倩云,李长钢.门冬酰胺酶对白血病患儿静脉血栓形成的研究进展[J].医学信息,2018,31(12):39.[doi:10.3969/j.issn.1006-1959.2018.12.013]
 HUANG Qian-yun,LI Chang-gang.Advances in the Treatment of Venous Thrombosis in Children with Leukemia by Asparaginase[J].Medical Information,2018,31(04):39.[doi:10.3969/j.issn.1006-1959.2018.12.013]
[2]韩怡波.儿童急淋大剂量甲氨蝶呤延迟解救的安全性研究[J].医学信息,2019,32(19):143.[doi:10.3969/j.issn.1006-1959.2019.19.046]
 HAN Yi-bo.Safety Study on Delayed Rescue of High-Dose Methotrexate in Children[J].Medical Information,2019,32(04):143.[doi:10.3969/j.issn.1006-1959.2019.19.046]
[3]刘婕妤,方智辉,李文克,等.复方磺胺甲噁唑对急性淋巴细胞白血病化疗后肺孢子菌肺炎的预防作用[J].医学信息,2020,33(12):135.[doi:10.3969/j.issn.1006-1959.2020.12.042]
 LIU Jie-yu,FANG Zhi-hui,LI Wen-ke,et al.Preventive Effect of Compound Sulfamethoxazole on Pneumocystis Pneumonia After Chemotherapy in Acute Lymphoblastic Leukemia[J].Medical Information,2020,33(04):135.[doi:10.3969/j.issn.1006-1959.2020.12.042]
[4]孙 燕,王绪栋,王兆辉,等.伴t(2;13)(q11;p11)特殊易位的儿童急性淋巴细胞白血病反复复发1例报道[J].医学信息,2021,34(20):190.[doi:10.3969/j.issn.1006-1959.2021.20.053]
[5]金 英.甲磺酸伊马替尼对难治性Ph染色体阳性急性淋巴细胞白血病患者免疫功能及生存率的影响[J].医学信息,2022,35(13):139.[doi:10.3969/j.issn.1006-1959.2022.13.033]
 JIN Ying.Effect of Imatinib Mesylate on Immune Function and Survival Rate in Patients with Refractory Ph Chromosome Positive Acute Lymphoblastic Leukemia[J].Medical Information,2022,35(04):139.[doi:10.3969/j.issn.1006-1959.2022.13.033]

更新日期/Last Update: 2020-02-15